Crispr Therapeutics shares tumble after significant earnings miss
SEATTLE - Know Labs, Inc. (NYSE American: KNW), a developer of non-invasive health monitoring technologies with a current market capitalization of $3.83 million, is set to undergo a significant change in ownership and leadership. According to InvestingPro data, the company currently operates with a weak financial health score of 1.24 and faces significant cash burn challenges. The company has entered into an agreement with Goldeneye 1995 LLC, an affiliate of fintech investor Greg Kidd, for the acquisition of a controlling interest in Know Labs.
Upon finalization of the transaction, expected in the third quarter of 2025, Greg Kidd will assume the roles of Chief Executive Officer and Chairman of the Board of Directors. The agreement terms stipulate that the buyer will purchase shares of Know Labs’ common stock, with the number of shares being determined by a formula involving 1,000 Bitcoin and additional cash to cover existing debts (current ratio of 0.07), preferred equity redemption, and working capital, divided by the share purchase price of $0.335. This price represents a significant discount to the current trading price of $0.51, though the stock has experienced a dramatic 92.59% decline year-to-date, as revealed by InvestingPro analysis.
Kidd, a former Ripple Chief Risk Officer, expressed enthusiasm for implementing a Bitcoin treasury strategy at Know Labs, anticipating favorable market and regulatory conditions to foster sustainable growth and enhance shareholder value. The company plans to adopt the multiple of net asset value (mNAV) metric to gauge the market valuation of its Bitcoin holdings, which, at the time of closing, are projected to represent 82% of the company’s market capitalization, assuming a Bitcoin price of $105,000.
Know Labs’ founder, Ron Erickson, will transition to the role of Vice Chairman of the Board and President of a new division focused on continuing the company’s proprietary diagnostic research.
The transaction has received unanimous approval from the Know Labs Board of Directors and is subject to shareholder approval and customary closing conditions.
Cohen & Company Capital Markets is serving as the exclusive financial advisor, with Lowenstein Sandler LLP and Sichenzia Ross Ference Carmel LLP providing legal advice to the buyer and Know Labs, respectively.
This strategic move marks a significant shift for Know Labs, positioning the company at the intersection of health technology and digital asset management. The information provided is based on a press release statement. For deeper insights into Know Labs’ Bitcoin strategy and comprehensive financial analysis, including 13 additional ProTips and advanced valuation metrics, explore the full research report available on InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.